Mersana Therapeutics Stock Today
MRSN Stock | USD 4.48 0.01 0.22% |
Performance15 of 100
| Odds Of DistressLess than 19
|
Mersana Therapeutics is selling at 4.48 as of the 29th of March 2024; that is -0.22 percent decrease since the beginning of the trading day. The stock's open price was 4.49. Mersana Therapeutics has less than a 19 % chance of experiencing some financial distress in the next two years of operation and had a good performance during the last 90 days. Equity ratings for Mersana Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 9th of April 2022 and ending today, the 29th of March 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 28th of June 2017 | Category Healthcare | Classification Health Care |
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates for cancer patients with unmet need. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts. Mersana Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 121.3 M outstanding shares of which 8.73 M shares are now shorted by private and institutional investors with about 3.03 trading days to cover. More on Mersana Therapeutics
Moving together with Mersana Stock
0.83 | EQ | Equillium Financial Report 9th of May 2024 | PairCorr |
Moving against Mersana Stock
0.89 | KA | Kineta Inc Financial Report 9th of May 2024 | PairCorr |
0.83 | ME | 23Andme Holding | PairCorr |
0.83 | VALN | Valneva SE ADR Financial Report 2nd of May 2024 | PairCorr |
0.82 | MEIP | MEI Pharma Financial Report 9th of May 2024 | PairCorr |
0.73 | MCRB | Seres Therapeutics Financial Report 14th of May 2024 | PairCorr |
0.49 | MGTX | MeiraGTx Holdings PLC Financial Report 9th of May 2024 | PairCorr |
0.46 | MBIO | Mustang Bio Report 3rd of April 2024 | PairCorr |
Follow Valuation Options Odds of Bankruptcy
Financial Report 14th of May 2024
Mersana Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Mersana Therapeutics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Mersana Therapeutics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
CEO President | MD Huber | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Thematic Idea | Cancer Fighters (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Cancer Fighters, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Average Analyst Recommendation Analysts covering Mersana Therapeutics report their recommendations after researching Mersana Therapeutics' financial statements, talking to executives and customers, or listening in on Mersana Therapeutics' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Mersana Therapeutics. The Mersana consensus assessment is calculated by taking the average forecast from all of the analysts covering Mersana Therapeutics. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength Based on the key indicators related to Mersana Therapeutics' liquidity, profitability, solvency, and operating efficiency, Mersana Therapeutics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in April. Financial strength of Mersana Therapeutics is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Mersana Therapeutics' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Mersana Therapeutics' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Mersana Therapeutics' financial leverage. It provides some insight into what part of Mersana Therapeutics' total assets is financed by creditors.
|
Mersana Therapeutics (MRSN) is traded on NASDAQ Exchange in USA. It is located in 840 Memorial Drive, Cambridge, MA, United States, 02139 and employs 123 people. Mersana Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 543.44 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Mersana Therapeutics's market, we take the total number of its shares issued and multiply it by Mersana Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Mersana Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 121.3 M outstanding shares of which 8.73 M shares are now shorted by private and institutional investors with about 3.03 trading days to cover.
Mersana Therapeutics currently holds about 225.13 M in cash with (168.88 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.32.
Check Mersana Therapeutics Probability Of Bankruptcy
Ownership AllocationMersana Therapeutics maintains a total of 121.3 Million outstanding shares. The majority of Mersana Therapeutics outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in Mersana Therapeutics to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in Mersana Therapeutics. Please pay attention to any change in the institutional holdings of Mersana Therapeutics as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Mersana Ownership Details
Mersana Stock Price Odds Analysis
Contingent on a normal probability distribution, the odds of Mersana Therapeutics jumping above the current price in 90 days from now is about 28.56%. The Mersana Therapeutics probability density function shows the probability of Mersana Therapeutics stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 2.1412. This indicates as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Mersana Therapeutics will likely underperform. Moreover, mersana Therapeutics has an alpha of 1.1356, implying that it can generate a 1.14 percent excess return over NYSE Composite after adjusting for the inherited market risk (beta).
Based on a normal probability distribution, the odds of Mersana Therapeutics to move above the current price in 90 days from now is about 28.56 (This Mersana Therapeutics probability density function shows the probability of Mersana Stock to fall within a particular range of prices over 90 days) .
Mersana Stock Institutional Holders
Institutional Holdings refers to the ownership stake in Mersana Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Mersana Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Mersana Therapeutics' value.Instituion | Recorded On | Shares | |
Longwood Capital Partners Llc | 2023-12-31 | 2.4 M | |
State Street Corporation | 2023-12-31 | 2.3 M | |
Geode Capital Management, Llc | 2023-12-31 | 2.3 M | |
Citadel Advisors Llc | 2023-09-30 | 1.6 M | |
5am Venture Management, Llc | 2023-12-31 | 1.3 M | |
Philosophy Capital Management Llc | 2023-12-31 | 1.3 M | |
Deutsche Bank Ag | 2023-12-31 | 1.1 M | |
Baker Bros Advisors Lp | 2023-12-31 | 1.1 M | |
Affinity Asset Advisors, Llc | 2023-12-31 | 1000 K | |
Ecor1 Capital, Llc | 2023-12-31 | 19.4 M | |
Vr Adviser, Llc | 2023-09-30 | 11.3 M |
Mersana Therapeutics Historical Income Statement
Mersana Therapeutics Income Statement is one of the three primary financial statements used for reporting Mersana's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Mersana Therapeutics revenue and expense. Mersana Therapeutics Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, Mersana Therapeutics' Interest Income is very stable compared to the past year. As of the 29th of March 2024, Interest Expense is likely to grow to about 4.3 M, while Depreciation And Amortization is likely to drop about 1.1 M. View More FundamentalsMersana Stock Against Markets
Picking the right benchmark for Mersana Therapeutics stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Mersana Therapeutics stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Mersana Therapeutics is critical whether you are bullish or bearish towards Mersana Therapeutics at a given time. Please also check how Mersana Therapeutics' historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Mersana Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Instant Ratings Now
Instant RatingsDetermine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |
All Next | Launch Module |
Mersana Therapeutics Corporate Directors
Mersana Therapeutics corporate directors refer to members of a Mersana Therapeutics board of directors. The board of directors generally takes responsibility for the Mersana Therapeutics' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Mersana Therapeutics' board members must vote for the resolution. The Mersana Therapeutics board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.Willard Dere | Independent Director | Profile | |
Andrew Hack | Independent Director | Profile | |
Lawrence Alleva | Independent Director | Profile | |
Kristen Hege | Independent Director | Profile |
How to buy Mersana Stock?
Before investing in Mersana Therapeutics, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Mersana Therapeutics. To buy Mersana Therapeutics stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of Mersana Therapeutics. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase Mersana Therapeutics stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located Mersana Therapeutics stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased Mersana Therapeutics stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Mersana Therapeutics, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Mersana Stock please use our How to Invest in Mersana Therapeutics guide.
Already Invested in Mersana Therapeutics?
The danger of trading Mersana Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Mersana Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Mersana Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Mersana Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Mersana Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Mersana Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Mersana Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Mersana Therapeutics Stock: Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mersana Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state. To learn how to invest in Mersana Stock, please use our How to Invest in Mersana Therapeutics guide.You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Complementary Tools for Mersana Stock analysis
When running Mersana Therapeutics' price analysis, check to measure Mersana Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mersana Therapeutics is operating at the current time. Most of Mersana Therapeutics' value examination focuses on studying past and present price action to predict the probability of Mersana Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mersana Therapeutics' price. Additionally, you may evaluate how the addition of Mersana Therapeutics to your portfolios can decrease your overall portfolio volatility.
Transaction History View history of all your transactions and understand their impact on performance | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |
Is Mersana Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mersana Therapeutics. If investors know Mersana will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mersana Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.48) | Revenue Per Share 0.317 | Quarterly Revenue Growth (0.27) | Return On Assets (0.38) | Return On Equity (2.66) |
The market value of Mersana Therapeutics is measured differently than its book value, which is the value of Mersana that is recorded on the company's balance sheet. Investors also form their own opinion of Mersana Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Mersana Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mersana Therapeutics' market value can be influenced by many factors that don't directly affect Mersana Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mersana Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Mersana Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mersana Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.